BACKGROUND AND OBJECTIVES: In humans, circulating CD4(+)CD25(high) T cells contain mainly regulatory T cells (Treg; FoxP3(+)IL-7Rα(low)), but a small subset is represented by activated effector T cells (Tact; FoxP3(-)IL-7Rα(high)). The balance between Tact and Treg may be important after transplantation. The aim of this study was first to analyze and correlate CD4(+)CD25(high) Tact and Treg with the clinical status of kidney transplant recipients and second to study prospectively the effect of two immunosuppressive regimens on Tact/Treg during the first year after transplantation. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: CD4(+)CD25(high) Tact and Treg were analyzed by flow cytometry, either retrospectively in 90 patients greater than 1 year after kidney transplantation (cross-sectional analysis) or prospectively in 35 patients receiving two immunosuppressive regimens after kidney transplantation (prospective analysis). RESULTS: A higher proportion of Tact and a lower proportion of Treg were found in the majority of kidney recipients. In chronic humoral rejection, a strikingly higher proportion of Tact was present. A subgroup of stable recipients receiving calcineurin inhibitor-free immunosuppression (mycophenolate mofetil, azathioprine, or sirolimus) had Tact values that were similar to healthy individuals. In the prospective analysis, the proportion of Tact significantly increased in both immunosuppression groups during the first year after transplantation. CONCLUSIONS: These data highlight distinct patterns in the proportion of circulating Tact depending on the clinical status of kidney recipients. Moreover, the prospective analysis demonstrated an increase in the proportion of Tact, regardless of the immunosuppressive regimen. The measurement of Tact, in addition to Treg, may become a useful immune monitoring tool after kidney transplantation.
BACKGROUND AND OBJECTIVES: In humans, circulating CD4(+)CD25(high) T cells contain mainly regulatory T cells (Treg; FoxP3(+)IL-7Rα(low)), but a small subset is represented by activated effector T cells (Tact; FoxP3(-)IL-7Rα(high)). The balance between Tact and Treg may be important after transplantation. The aim of this study was first to analyze and correlate CD4(+)CD25(high) Tact and Treg with the clinical status of kidney transplant recipients and second to study prospectively the effect of two immunosuppressive regimens on Tact/Treg during the first year after transplantation. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: CD4(+)CD25(high) Tact and Treg were analyzed by flow cytometry, either retrospectively in 90 patients greater than 1 year after kidney transplantation (cross-sectional analysis) or prospectively in 35 patients receiving two immunosuppressive regimens after kidney transplantation (prospective analysis). RESULTS: A higher proportion of Tact and a lower proportion of Treg were found in the majority of kidney recipients. In chronic humoral rejection, a strikingly higher proportion of Tact was present. A subgroup of stable recipients receiving calcineurin inhibitor-free immunosuppression (mycophenolate mofetil, azathioprine, or sirolimus) had Tact values that were similar to healthy individuals. In the prospective analysis, the proportion of Tact significantly increased in both immunosuppression groups during the first year after transplantation. CONCLUSIONS: These data highlight distinct patterns in the proportion of circulating Tact depending on the clinical status of kidney recipients. Moreover, the prospective analysis demonstrated an increase in the proportion of Tact, regardless of the immunosuppressive regimen. The measurement of Tact, in addition to Treg, may become a useful immune monitoring tool after kidney transplantation.
Authors: Eric M Gibney; Linda R Cagle; Brian Freed; Stephanie E Warnell; Larry Chan; Alexander C Wiseman Journal: Nephrol Dial Transplant Date: 2006-04-27 Impact factor: 5.992
Authors: Jeroen J A Coenen; Hans J P M Koenen; Esther van Rijssen; Luuk B Hilbrands; Irma Joosten Journal: Blood Date: 2005-10-06 Impact factor: 22.113
Authors: David San Segundo; Juan Carlos Ruiz; María Izquierdo; Gema Fernández-Fresnedo; Carlos Gómez-Alamillo; Ramón Merino; María Jesús Benito; Eva Cacho; Emilio Rodrigo; Rosa Palomar; Marcos López-Hoyos; Manuel Arias Journal: Transplantation Date: 2006-08-27 Impact factor: 4.939
Authors: S Gurkan; Y Luan; N Dhillon; S R Allam; T Montague; J S Bromberg; S Ames; S Lerner; Z Ebcioglu; V Nair; R Dinavahi; V Sehgal; P Heeger; B Schroppel; B Murphy Journal: Am J Transplant Date: 2010-09 Impact factor: 8.086
Authors: Nabila Seddiki; Brigitte Santner-Nanan; Jeff Martinson; John Zaunders; Sarah Sasson; Alan Landay; Michael Solomon; Warwick Selby; Stephen I Alexander; Ralph Nanan; Anthony Kelleher; Barbara Fazekas de St Groth Journal: J Exp Med Date: 2006-07-03 Impact factor: 14.307
Authors: Weihong Liu; Amy L Putnam; Zhou Xu-Yu; Gregory L Szot; Michael R Lee; Shirley Zhu; Peter A Gottlieb; Philipp Kapranov; Thomas R Gingeras; Barbara Fazekas de St Groth; Carol Clayberger; David M Soper; Steven F Ziegler; Jeffrey A Bluestone Journal: J Exp Med Date: 2006-07-03 Impact factor: 14.307
Authors: Pablo J E J van de Berg; Eveline C Hoevenaars; Si-La Yong; Karlijn A M I van Donselaar-van der Pant; Anne van Tellingen; Sandrine Florquin; René A W van Lier; Fréderike J Bemelman; Ineke J M ten Berge Journal: Immunology Date: 2012-06 Impact factor: 7.397
Authors: Dorien Feyaerts; Joshua Gillard; Bram van Cranenbroek; Lina Rigodanzo Marins; Mariam M S Baghdady; Gaia Comitini; A Titia Lely; Henk W van Hamersvelt; Olivier W H van der Heijden; Irma Joosten; Renate G van der Molen Journal: Front Immunol Date: 2021-10-28 Impact factor: 7.561
Authors: Fatina I Fadel; Eman A Elghoroury; Manal F Elshamaa; Hafez M Bazaraa; Doaa M Salah; Neemat M A Kassem; Mona H Ibrahim; Gamila S El-Saaid; Soha A Nasr; Hala M Koura Journal: Int J Biomed Sci Date: 2015-09